MX2022011583A - Dpp3 en pacientes infectados con coronavirus. - Google Patents

Dpp3 en pacientes infectados con coronavirus.

Info

Publication number
MX2022011583A
MX2022011583A MX2022011583A MX2022011583A MX2022011583A MX 2022011583 A MX2022011583 A MX 2022011583A MX 2022011583 A MX2022011583 A MX 2022011583A MX 2022011583 A MX2022011583 A MX 2022011583A MX 2022011583 A MX2022011583 A MX 2022011583A
Authority
MX
Mexico
Prior art keywords
dpp3
level
therapy
correlating
determined
Prior art date
Application number
MX2022011583A
Other languages
English (en)
Inventor
Andreas Bergmann
Original Assignee
4TEEN4 Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20179763.6A external-priority patent/EP3922993A1/en
Application filed by 4TEEN4 Pharmaceuticals GmbH filed Critical 4TEEN4 Pharmaceuticals GmbH
Publication of MX2022011583A publication Critical patent/MX2022011583A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La materia objeto de la presente invención es un método para (a) diagnosticar o predecir el riesgo de deterioro potencialmente mortal o un evento adverso o (b) diagnosticar o pronosticar la gravedad de o (c) predecir o monitorear el éxito de una terapia o intervención o (d) guía de la terapia o estratificación de la terapia o (e) manejo del paciente en un paciente infectado con un coronavirus, el método comprende: determinar el nivel de dipeptidil peptidasa 3 (DPP3) en una muestra de fluido corporal del paciente, comparar el nivel de DPP3 determinada a un umbral predeterminado, y correlacionar el nivel de DPP3 determinada con el riesgo de deterioro potencialmente mortal o un evento adverso, o correlacionar el nivel de DPP3 determinada con la gravedad, o correlacionar el nivel de DPP3 determinada con el éxito de una terapia, o correlacionar el nivel de DPP3 con una cierta terapia o intervención, o correlacionar el nivel de DPP3 con el manejo del paciente. La materia objeto de la presente invención es un inhibidor de la actividad de DPP3 para usarse en la terapia o intervención en un paciente infectado con un coronavirus.
MX2022011583A 2020-03-16 2021-03-15 Dpp3 en pacientes infectados con coronavirus. MX2022011583A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062990166P 2020-03-16 2020-03-16
EP20163419 2020-03-16
US202063015205P 2020-04-24 2020-04-24
EP20179763.6A EP3922993A1 (en) 2020-06-12 2020-06-12 Dpp3 in patients infected with coronavirus
PCT/EP2021/056579 WO2021185786A1 (en) 2020-03-16 2021-03-15 Dpp3 in patients infected with coronavirus

Publications (1)

Publication Number Publication Date
MX2022011583A true MX2022011583A (es) 2022-10-18

Family

ID=74870834

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011583A MX2022011583A (es) 2020-03-16 2021-03-15 Dpp3 en pacientes infectados con coronavirus.

Country Status (9)

Country Link
US (1) US20230213519A1 (es)
EP (1) EP4121763A1 (es)
JP (1) JP2023518731A (es)
CN (1) CN115769076A (es)
AU (1) AU2021237689A1 (es)
BR (1) BR112022017277A2 (es)
CA (1) CA3171332A1 (es)
MX (1) MX2022011583A (es)
WO (1) WO2021185786A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024126793A1 (en) 2022-12-15 2024-06-20 4TEEN4 Pharmaceuticals GmbH Dpp3 inhibitor for improvement of pulmonary function in critically ill patients

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
JPS6188884A (ja) 1984-10-04 1986-05-07 Sankyo Co Ltd エンケフアリナ−ゼｂ阻害物質およびその製法
AU634716B2 (en) 1988-08-01 1993-03-04 Ciba Corning Diagnostics Corp. Method for detection of an analyte using acridinium esters and liposomes
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU633698B2 (en) 1990-01-12 1993-02-04 Amgen Fremont Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992020791A1 (en) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
IL160289A0 (en) 2001-08-30 2004-07-25 Biorexis Pharmaceutical Corp Modified transferrin fusion proteins
EP2298278B1 (en) 2002-06-07 2015-11-11 Dyax Corp. Prevention and reduction of blood loss and inflammatory response
US20050164301A1 (en) 2003-10-24 2005-07-28 Avidia Research Institute LDL receptor class A and EGF domain monomers and multimers
US20100028995A1 (en) 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
AU2005287557B2 (en) 2004-09-21 2011-10-13 Biontech Ag Use of microproteins as tryptase inhibitors
ATE527353T1 (de) 2007-12-19 2011-10-15 Affibody Ab Pdgf-bindendes polypeptid aus protein a
NZ592591A (en) 2008-11-03 2012-04-27 Molecular Partners Ag Binding proteins comprising ankyrin repeast domains that inhibit the vegf-a receptor interaction
BR112012004314A2 (pt) 2009-08-27 2016-11-29 Covagen Ag compostos de ligação a il-17 e usos medicinais desses compostos
CA2778871C (en) 2009-12-14 2017-08-01 Scil Proteins Gmbh Modified ubiquitin proteins having a specific binding activity for the extradomain b of fibronectin
WO2011154420A2 (en) 2010-06-08 2011-12-15 Pieris Ag Tear lipocalin muteins binding il-4 r alpha
CN105228633A (zh) 2013-01-28 2016-01-06 新天然替代品公司 用于由氧化应激和/或氧化还原失衡产生的病理状态的全身治疗的组合物
JP2019520550A (ja) 2016-04-21 2019-07-18 スフィンゴテック セラピューティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ３の定量方法および治療方法
CN111542548A (zh) 2017-10-25 2020-08-14 4Teen4制药有限公司 针对并结合于特异性dpp3表位的dpp3结合剂及其在预防或治疗与氧化应激相关的疾病/急性病状中的用途

Also Published As

Publication number Publication date
AU2021237689A1 (en) 2022-11-03
US20230213519A1 (en) 2023-07-06
JP2023518731A (ja) 2023-05-08
BR112022017277A2 (pt) 2022-10-18
CN115769076A (zh) 2023-03-07
WO2021185786A1 (en) 2021-09-23
EP4121763A1 (en) 2023-01-25
CA3171332A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
Tayyib et al. Saudi Arabian adult intensive care unit pressure ulcer incidence and risk factors: a prospective cohort study
Beidler et al. Multiplexed analysis of matrix metalloproteinases in leg ulcer tissue of patients with chronic venous insufficiency before and after compression therapy
Hopkins et al. Does time to endoscopic sinus surgery impact outcomes in Chronic Rhinosinusitis? Prospective findings from the National Comparative Audit of Surgery for Nasal Polyposis and Chronic Rhinosinusitis
Frantz et al. Baseline and serial brain natriuretic peptide level predicts 5-year overall survival in patients with pulmonary arterial hypertension: data from the REVEAL registry
Feldman A quantitative definition of severe psoriasis for use in clinical trials
MX2022011583A (es) Dpp3 en pacientes infectados con coronavirus.
Belba et al. Epidemiology and outcome analysis of sepsis and organ dysfunction/failure after burns
Perrot et al. Patient phenotypes in fibromyalgia comorbid with systemic sclerosis or rheumatoid arthritis: influence of diagnostic and screening tests. Screening with the FiRST questionnaire, diagnosis with the ACR 1990 and revised ACR 2010 criteria
Kapoor et al. Fibromyalgia in patients with rheumatoid arthritis: driven by depression or joint damage?
MX2022002432A (es) Orientacion terapeutica y/o monitoreo terapeutico para el tratamiento de choques.
Gupta et al. The prognostic significance of cardiac structure and function in atrial fibrillation: The ENGAGE AF–TIMI 48 Echocardiographic Substudy
Sebbag et al. Investigation of Schirmer tear test-1 for measurement of tear production in cats in various environmental settings and with different test durations
Chung et al. Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry
Tay et al. Toe pressure in predicting diabetic foot ulcer healing: a systematic review and meta-analysis
MX2019000003A (es) Adrenomodulina para evaluar la congestión en un individuo con insuficiencia cardiaca aguda.
MX2021003164A (es) Perfiles de hidroximetilación de adn circulante en la evaluación de lesiones pancreáticas.
Scharbatke et al. Association of improvement in pain with therapeutic response as determined by individual improvement criteria in patients with rheumatoid arthritis
Marcadis et al. Successful parathyroidectomy guided by intraoperative parathyroid hormone monitoring for primary hyperparathyroidism is preserved in mild and moderate renal insufficiency
WO2023235768A3 (en) Biomarker-based risk model to predict death and persistent multiple organ dysfunction syndrome in pediatric septic shock
Walsh et al. Treatment patterns with disease-modifying antirheumatic drugs in US Veterans with newly diagnosed rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis
Williams et al. WIfi scoring: a reliable tool for risk stratification in the diabetic foot clinic
MX2022012600A (es) Ofatumumab para el tratamiento de ms mientras se mantiene la igg en el suero.
Kapur et al. Real world validation of VTE risk models in newly diagnosed multiple myeloma in a community setting
Wham et al. Prehospital ETCO2 is predictive of death in intubated and non-intubated patients
Verhoeven et al. THU0406 ULTRASONOGRAPHIC INVOLVEMENT OF THE ANTERIOR CHEST WALL IN SPONDYLOARTHRITIS, A FIVE YEARS FOLLOW UP STUDY